Stroke care in Australia: why is it still the poor cousin of health care?
Author: Stephen P J Macdonald
Published online: 5 August 2013
To the Editor: In their editorial on stroke care in Australia, Hoffman and Lindley state “only 7% of ischaemic stroke patients received thrombolysis treatment, yet for every 100 patients who receive it, there are up to 10 extra independent survivors”,1 citing the most recent meta-analysis.2 This research also found a significant increase in the risk of early death with thrombolysis, mostly from intracranial haemorrhage. For the individual patient, predicting final neurological outcome is difficult in the early hours after the onset of stroke. Patients considering thrombolysis treatment must weigh up an increased risk of early death against possible improvement in final function if they survive. In addition, any benefits from thrombolysis appear modest at best.
The third International Stroke Trial (IST-3), the most recently published and largest randomised trial of thrombolysis in stroke, in fact showed no improvement in the proportion of patients alive and independent at 6 months.3 Hoffman and Lindley describe a number of evidence–practice gaps, including early assessment for transient ischaemic attack and access to multidisciplinary stroke unit care. Patients and the community may be better served by directing resources to such areas where stronger evidence of overall benefit exists.
Competing interests
References
- Hoffman TC, Lindley RI. Stroke care in Australia: why is it still the poor cousin of health care? Med J Aust 2013; 198: 246-247. 0_BABEIJII
- Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379: 2364-2372. 0_i1142858
- Sandercock P, Wardlaw JM, Lindley RI, et al; IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-2363. 0_i1142862
Getting on the Same Page: Why Australia Needs a National Maternity Early Warning System (MEWS) Chart
Briony A. Cutts, Lucy Bowyer, Nisha Khot, Sandra Lowe, Stefan C. Kane
Data for Equity: Can Linked Administrative Data Inform Pathways to More Equitable Child Health?
Sarah Gray, Shuaijun Guo, Meredith O'Connor, Elodie O'Connor, Katrina Williams, Hannah Badland, Susan Woolfenden, Josie Dickerson, Gerry Redmond, Marnie Downes, Sharon R. Goldfeld
Specialty College Selection: Why Change is Critical to Support a Future Rural Workforce
Matthew R. McGrail, Jenny May AM, Katherine Logan
The number of cancer‐related deaths that could be attributable to spatial disparities in survival in Australia, 2010–2019: a retrospective population‐based cohort study
Charlotte K Bainomugisa, Jessica Cameron, Paramita Dasgupta, Peter Baade
Differentiated and simplified oral HIV pre‐exposure prophylaxis (PrEP) models hold the key to virtually eliminating HIV transmission in Australia by 2030
Tyson Arapali, Sarah Warzywoda, Anthony K J Smith, Curtis Chan, Timothy R Broady, Erin Sullivan, Catherine MacPhail, Mohamed A Hammoud, Alexander Dowell‐Day, Benjamin R Bavinton
Non‐technical errors associated with deaths in surgical care, Australia, 2012–2019, by surgical specialty (Australian and New Zealand Audit of Surgical Mortality): a retrospective cohort study
Jesse Ey, Victoria Kollias, Octavia Lee, Kelly Hou, Matheesha Herath, John B North, Ellie Treloar, Suzanne Edwards, Martin Bruening, Adam J Wells, Guy J Maddern